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Abstract
Aims/hypothesis The innate immune cells, invariant natural
killer T cells (iNKTcells), are implicated in the pathogenesis
of psoriasis, an inflammatory condition associated with
obesity and other metabolic diseases, such as diabetes and
dyslipidaemia. We observed an improvement in psoriasis
severity in a patient within days of starting treatment with an
incretin-mimetic, glucagon-like peptide-1 (GLP-1) receptor
agonist. This was independent of change in glycaemic control.
We proposed that this unexpected clinical outcome resulted
from a direct effect of GLP-1 on iNKTcells.
Methods We measured circulating and psoriatic plaque
iNKT cell numbers in two patients with type 2 diabetes
and psoriasis before and after commencing GLP-1 analogue
therapy. In addition, we investigated the in vitro effects of
GLP-1 on iNKT cells and looked for a functional GLP-1
receptor on these cells.
Results The Psoriasis Area and Severity Index improved in
both patients following 6 weeks of GLP-1 analogue
therapy. This was associated with an alteration in iNKT
cell number, with an increased number in the circulation
and a decreased number in psoriatic plaques. The GLP-1
receptor was expressed on iNKT cells, and GLP-1 induced
a dose-dependent inhibition of iNKT cell cytokine secre-
tion, but not cytolytic degranulation in vitro.
Conclusions/interpretation The clinical effect observed and
the direct interaction between GLP-1 and the immune
system raise the possibility of therapeutic applications for
GLP-1 in inflammatory conditions such as psoriasis.
Keywords Anti-inflammatory. CREB . Diabetes . GLP-1
analogue . GLP-1 receptor. Innate immune system .
Invariant NKT cells . Obesity. Psoriasis
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Introduction
Psoriasis is an immune-mediated disease associated with
obesity and other metabolic disorders, such as diabetes and
dyslipidaemia [1–4]. Patients with psoriasis are more likely
to be obese than non-psoriatic controls. Obesity is more
prevalent in patients with severe rather than mild psoriasis
[1]. Both conditions are associated with chronic systemic
inflammatory activation [5, 6] and an increased risk of
cardiovascular morbidity and mortality [7–9].
We have previously reported that obesity is associated
with innate immune cell dysfunction, a key feature of
psoriasis [10, 11]. We have demonstrated that, compared
with lean individuals, obese individuals have decreased
circulating natural killer cell number and function [10], and
also have lower invariant natural killer T cell (iNKT cell)
accumulation in the omentum [11]. iNKT cells are a rare
subset of innate T cells that exert multiple immunoregula-
tory functions. They recognise glycolipid antigens, such as
the marine sponge-derived glycolipid α-galactosylceramide
(α-GalCer), presented on the MHC-like molecule, CD1d.
Upon stimulation, iNKT cells can rapidly produce multiple
cytokines that direct the immune response towards a pro-
inflammatory (Th1 or Th17) or an anti-inflammatory (Th2)
bias [12]. iNKT cells are implicated in the pathogenesis of
various obesity-related diseases, including psoriasis [13],
cancer [14, 15] and arthritis [16, 17].
The incretin pathway is a therapeutic target for obesity
and diabetes [18]. The incretin effect results from release of
hormones such as glucagon-like peptide-1 (GLP-1) from
intestinal cells in response to glucose ingestion, enhancing
insulin release and reducing postprandial excursions of
plasma glucose. Long-acting GLP-1 analogues, GLP-1
receptor agonists and inhibitors of GLP-1 enzymatic
degradation are increasingly used in type 2 diabetes to
improve glycaemic control and enhance weight loss. The
GLP-1 receptor (GLP-1R) is widely distributed in pancre-
atic islets, brain, heart, kidney and the gastrointestinal tract
[19]. GLP-1R has also been demonstrated in murine
immune tissues [20], and on T and B lymphocytes from
mice [20, 21] and humans [22]. Several reports indicate a
role for the incretin hormones in regulation and migration
of murine [20, 21, 23] and human [22] T lymphocytes. The
effects of incretin hormones on human iNKT cell function
have not yet been described.
In the present study, we observed an unexpected
beneficial effect on co-existing psoriasis in an obese, type 2
diabetes patient on GLP-1 therapy. The improvement in
psoriasis symptoms began within days, and prior to weight
loss or significant improvements in glycaemic control. We
hypothesised that GLP-1 may influence psoriasis severity by
interacting directly with the innate immune system, in
particular iNKTcells.
Methods
Index patient The index patient was a 60-year-old woman
with type 2 diabetes and BMI 37 kg/m2. She had had
extensive, refractory psoriasis since childhood, requiring
several inpatient admissions and multiple treatments with
systemic agents. Prior to treatment she had a Psoriasis Area
and Severity Index (PASI) greater than 15. She complained
of extensive, itchy psoriasis causing marked sleep disrup-
tion. A GLP-1R agonist, exenatide, was initiated for
treatment of type 2 diabetes. Within 2 days she reported
an improvement in psoriasis severity, with decreased itch
and less sleep disruption. By 2 weeks the PASI was 10.5.
This patient experienced nausea in association with exena-
tide, requiring discontinuation after 2 months of treatment.
The psoriasis symptoms quickly began to recur, with PASI
reaching 15.3 by the end of 2 weeks. The patient then
commenced a trial of liraglutide, a GLP-1 analogue, and
reported prompt improvement in itch and thinning of
psoriatic plaques. By the end of 3 weeks the PASI had
fallen to 10.2. After 9 months of liraglutide therapy
psoriasis symptoms remain stable (PASI 10.5).
Other participants Following the observed improvement in
psoriasis in the index patient, we started two additional
obese participants with psoriasis and well-controlled type 2
diabetes on liraglutide. St Vincent’s University Hospital
Medical Research Ethics Committee approved this study, and
written informed consent was obtained from each participant
prior to the start of any research activities. We characterised
the circulatory and plaque levels of iNKTcells at baseline and
following 6 weeks of GLP-1 analogue therapy in these two
participants. The clinical improvement in the index patient
was unexpected so we were unable to study the immunolo-
gical profile before and after treatment in this case.
Enumeration of iNKT cells by flow cytometry Peripheral
blood mononuclear cells (PBMCs) were isolated from
patients by density gradient centrifugation (300 g) over
Lymphoprep (Nycomed, Oslo, Norway). Skin biopsies were
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obtained from psoriasis plaques and digested with 0.5%
(wt/vol.) collagenase type 1A (Sigma-Aldrich, Wicklow,
Ireland) to obtain single-cell suspensions. iNKT cells were
enumerated by staining with a pairing of phycoerythrin-
conjugated anti-iNKT cell monoclonal antibody (mAb)
(clone 6B11) and phycoerythrin-Cy5-conjugated anti-CD3
mAb, or with FITC-conjugated anti-Vα24 T cell receptor
(TCR) mAb and a phycoerythrin-conjugated anti-Vβ11
mAb. Cells were acquired using a flow cytometer (FACS
Caliber, BD Biosciences, NJ, USA) and analysed using Cell
Quest Pro (BD Biosciences) using Flow Minus One
controls. iNKT cell numbers are expressed as a percentage
of lymphocytes or T cells.
Generation of iNKT cell lines PBMCs were isolated from
healthy blood donors as previously described. iNKT cells
were isolated from PBMCs by magnetic bead separation
with an anti-iNKT cell bead (Miltenyi Biotec, Bergisch-
Gladbach, Germany). iNKT cells were further enriched by
flow cytometric sorting of 6B11-positive cells using a cell
sorter (FACS Aria; BD Biosciences). Sorted iNKT cells
were expanded in vitro by culturing 1,000 iNKT cells in
complete RPMI medium and stimulating them with 1 μg/ml
phytohaemagglutinin (Sigma-Aldrich) and 250 U/ml IL-2
(R&D Systems, Oxford, UK) in the presence of an excess
(2×105) of irradiated allogeneic PBMCs prepared from two
donors. After 24 and 48 h, cell culture medium was
replaced with medium containing 250 U/ml IL-2. Cell lines
were expanded for 2 to 4 weeks in the presence of IL-2
medium. Purity and phenotype of iNKT cell lines were
assessed by flow cytometry after staining the cells with
mAbs specific for CD3, 6B11, Vα24, Vβ11, CD4 and
CD8.
Glycolipid preparation α-GalCer (Funakoshi, Tokyo, Japan)
stocks were prepared by suspending solid α-GalCer in
DMSO to a final concentration of 1 mg/ml by heating for
2 min at 80°C, followed by sonication for 5 min and
vortexing for 1 min. These stocks were stored at −20°C.
Analysis of cytokine secretion by iNKT cells iNKT cells
were stimulated in vitro using CD1d-transfected C1R cells
pulsed with glycolipid. For the cytokine production assay, 2×
105 C1R-transfected cells were cultured in round-bottomed
96-well tissue culture plates and pulsed with 100 ng/ml
glycolipid antigen for 1 h before adding an equal number of
iNKTcells, with or without GLP-1 (1–150 μg) or the GLP-1
analogue liraglutide (15 μg/ml). Phorbol myristate acetate
(PMA) (10 ng/ml) and ionomycin (1 μg/ml) were used as a
positive control, and iNKT cells in the absence of C1R cells
and αGalCer as a negative control. Pre-treatment with
10 μg/ml exendin 9-39 was used in blocking experiments
prior to stimulation and GLP-1 treatment. After 24 h,
supernatant fraction concentrations of IFN-γ and IL-4 were
determined by ELISA.
Analysis of cytolytic degranulation of iNKT cells iNKT
cells, treated with or without the GLP-1 analogue (15 μg/ml),
were co-cultured with CD1d+ HeLa cells and Jurkat target
cells. Cells were examined by flow cytometric analysis for
CD107a expression on 6B11-positive effector iNKT cells. In
these experiments, iNKT cells and target cells were co-
cultured for 4 h in the presence of anti-CD107a mAb and
monensin (25 μmol/l; Sigma-Aldrich). Monensin was used
to prevent re-internalisation of CD107a.
Detection and quantification of GLP1R mRNA RNA was
extracted from previously described iNKT cell lines using
a total RNA isolation kit as per the manufacturer’s
instructions (Macherey-Nagel; Thermo Fisher Scientific,
Loughborough, UK). A cell concentration of 1.5×106
was used. The RNA was quantified using the nano-drop
system and qualitatively assessed using a bioanalyser
(Agilent Biosystems, Cork, Ireland). The integrity of the
RNAwas determined by the RNA integrity number (RIN).
A starting concentration of 1 μg RNAwas used for cDNA
synthesis using a cDNA synthesis kit (Omniscript; Qiagen,
Crawley, UK) including a negative control. The 50 μl PCR
reaction mix was made up using a kit (GoTaq Flexi kit;
Promega, Madison, WI, USA), with 10 μl reaction buffer,
1 mmol/l MgCl2, 0.2 mm dNTPs, 0.2 μmol/l forward and
reverse primers, and 1.25 U Taq polymerase using a 1:10
dilution of stock cDNA as the PCR template. GLP1R
expression analysis was quantified using the reference
gene β-actin. The optimal PCR conditions for GLP1R and
β-actin were: 95°C for 3 min; 35 cycles at 95°C for 30 s,
57°C for 30 s and 72°C for 30 s; and then 72°C for 7 min.
No template and negative controls containing water-based
cDNA were used to rule out component contamination.
Results were visualised by means of 1% agarose gels and
using the AutoChemi System (UVP BioImaging Systems,
Cambridge, UK). Real-time PCR was performed using
Qiagen QuantiTect primers for GLP1R and β-actin in
cultured iNKT cell lines and in HEK 293, which are
negative for GLP1R. The master mix was comprised of
12.5 μl SYBR Green (Promega), 1 μl of a 1:10 dilution of
stock cDNA as the PCR template and 2.5 μl of primer
assay. No template controls were used to eliminate reagent
contamination. The RT-PCR conditions were 95°C for
10 min and 40 cycles of 94°C for 15 s, 55°C for 30 s and
72°C for 30 s.
Primers for GLP1R were: forward 5-TCAAGGTCA
ACGGCTTATTAG-3, reverse 5-TAACGTGTCCCTAGAT
GAACC-3. Primers for β-actin were: forward 5-CACCTT
CACCGTTCCAGTT-3, reverse 5-CTCTTCCAGCCAGCC
TTCCTTCCT-3.
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Investigation of GLP-1R abundance by intracellular flow
cytometry iNKT cells (2×105) were surface-stained with
the iNKT cell TCR mAb anti-6B11 (FITC), anti-CD4 and
anti-CD3 (APC). Cells were fixed using 4% paraformalde-
hyde [wt/vol.], permeabilised using 0.2% saponin and then
incubated with the anti-GLP-1R mAb (phycoerythrin) or
relevant isotype control. Cells then underwent flow cytom-
etry and results were analysed using FlowJo software
(Treestar, Ashland, OR, USA).
cAMP assay iNKT cells (1.5×106) were seeded in the
presence or absence of plate-bound anti-CD3 (2 μg/ml) and
cultured with the GLP-1 analogue (15 μg/ml) for the indicated
times. As a positive control, cells were incubated for 15 min
with the cAMP phosphodiesterase inhibitor, 3-isobutyl-1-
methylxanthine (500 μmol/l), and then stimulated for another
30 min with forskolin (30 μmol/l). Cells were washed twice
with ice-cold PBS (1 ml), lysed in lysis buffer (250 μl) and
subjected to two freeze–thaw cycles. Lysates were assessed
for levels of intracellular cAMP using a cAMP assessment kit
as per the manufacturer's instructions (R&D Systems).
Measurement of cAMP response element-binding protein
phosphorylation iNKT cells (2×106) were seeded in the
presence or absence of plate-bound anti-CD3 (2 μg/ml) and
cultured with the GLP-1 analogue (15 μg/ml) or lipopoly-
saccharide (100 ng/ml) for the indicated times. Cells were
washed in ice-cold PBS (1 ml) and lysed in RIPA lysis
buffer (50 μl) (50 mmol/l Tris–HCl, pH 7.5, containing
150 mmol/l NaCl, 1% [wt/vol.] IGEPAL, 1% [wt/vol.]
sodium deoxycholate, 1 mmol/l Na3VO4, 1 mmol/l dithio-
threitol, 1 mmol/l phenylmethylsulfonyl fluoride and
protease inhibitor mixture consisting of leupeptin [25 μg/
ml], aprotinin [25 μg/ml], benzamidine [1 mmol/l] and
trypsin inhibitor [10 μg/ml]). Cell lysates were centrifuged
at 12,000 g for 10 min. The supernatant fractions were
mixed with 4× sample loading buffer (0.125 mol/l Tris–
HCl, pH 6.8, containing 20% [wt/vol.] glycerol, 4% [wt/
vol.] SDS, 1.4 mol/l 2-mercaptoethanol and 0.0025% [wt/
vol.] Bromophenol Blue). Samples were then resolved by
SDS-PAGE, transferred to nitrocellulose membrane and
probed for immunoreactivity using anti-phospho-cAMP
response element-binding protein (CREB) (Santa Cruz,
Heidelberg, Germany), anti-CREB (Santa Cruz) and anti-
β-actin (Sigma-Aldrich) specific antibodies. Immunoreac-
tive bands were detected using an infrared imaging system
(Odyssey; LI-COR Biosciences, Lincoln, NE, USA)
according to the manufacturer’s instructions.
Statistical analysis All statistical analyses were performed
with Prism version 5.0b software (GraphPad Software, San
Diego, CA, USA). Data are presented as mean ± SEM.
Groups were compared using Student’s t test or Mann–
Whitney U test as appropriate. p values of p<0.05 were
considered statistically significant.
Results
GLP-1 analogue therapy improves psoriasis and is associated
with a redistribution of iNKTcells between the circulation and
psoriatic plaques Psoriasis improved in both participants
Table 1 Clinical profile and iNKT cell data from non-index
participants 1 and 2 at baseline and 6 weeks following commencement
of GLP-1 analogue treatment
Variable Participant 1 Participant 2
Age (years) 48 49
Sex Male Male
Diabetes duration (years) 2 4
Co-morbidities
Hypertension Yes Yes
Dyslipidaemia No Yes
Osteoarthritis Yes No
Relevant medications
Metformin Yes Yes
Aspirin Yes Yes
Diuretic Yes No
Calcium channel blocker Yes Yes
ACE inhibitor No Yes
Statin No Yes
Psoriasis treatmenta No No
Body weight (kg)
Baseline 159.1 137.8
6 weeks 154.0 131.6
BMI (kg/m2)
Baseline 48.0 43.0
6 weeks 46.5 41.1
HbA1c, % (mmol/mol)
Baseline 5.7 (38) 5.9 (40)
6 weeks 5.6 (37) 5.8 (39)
PASI
Baseline 13.2 4.8
6 weeks 10.8 3.8
iNKT cells (% of lymphocytes)
Skin
Baseline 2.16 0.32
6 weeks 0.07 0.00
Blood
Baseline 0.15 0.16
6 weeks 0.6 0.57
a Topical or oral treatment within previous 6 months
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following 6 weeks’ treatment with liraglutide. The PASI
improved from 13.2 to 10.8 in participant 1 and from 4.8 to
3.8 in participant 2. iNKT cell number increased in the
circulation following 6 weeks of therapy. This was
accompanied by a decrease in iNKT cell number in
psoriatic plaques (Table 1).
iNKT cells express GLP1R and signal in response to
GLP-1 Given the capacity of the GLP-1 agonist to promote
such clear re-distribution of iNKT cells from the skin into
the circulation, we next assessed the ability of GLP-1 to act
directly on iNKT cells. This was addressed by initially
probing for GLP1R expression in these cells and investi-
gating the ability of GLP-1 to trigger downstream intracel-
lular signalling pathways. We examined polyclonal iNKT
cell lines for human GLP1R by conventional PCR and real-
time PCR. All lines were found to express GLP1R mRNA
(Fig. 1a, b). To further complement this finding, intracel-
lular flow cytometry was employed to confirm that GLP-1R
is also produced at the protein level in iNKTcells (Fig. 1c).
We next assessed the ability of GLP-1R-producing iNKT
cells to signal in response to GLP-1. Given that GLP-1R is
a G-protein-coupled receptor that couples to the stimulatory
Gs protein and activates adenylate cyclase and hence cAMP
production, we examined the ability of GLP-1 to regulate
levels of cAMP in iNKT cells. Stimulation of GLP-1R by
the GLP-1 analogue resulted in a time-dependent upregu-
lation of levels of cAMP (Fig. 2a). While levels of cAMP
were somewhat reduced in CD3-activated iNKT cells,
stimulation of GLP-1R in these latter cells also showed
time-dependent increases in levels of cAMP. Given that
cAMP can activate the downstream enzyme protein kinase A,
which in turn phosphorylates the transcription factor
CREB, we were keen to show that the GLP-1R could
also trigger these downstream signalling components.
Stimulation of GLP-1R induced a time-dependent phos-
phorlyation of the transcription factor CREB and was
further augmented when iNKT cells were activated with
CD3 (Fig. 2b). There was no change in total levels of
CREB or the housekeeping protein β-actin. These findings
confirm that iNKT cells produce a functional GLP-1R,
which can respond to GLP-1 and trigger downstream
signal transduction cascades.
GLP-1 modulates iNKTcell cytokine production in a GLP-
1R-dependent manner We next investigated the effects of
GLP-1 on the function of iNKT cells. Native GLP-1
increased cytokine production by approximately two fold
in resting iNKT cells (IFN-γ p<0.0001, IL-4 p<0.005;
Fig. 3a, b). This occurred independently of αGalCer.
Fig. 1 iNKT cells express
GLP-1R. a Expression of
GLP1R mRNA by iNKT cell
lines as determined by RT-PCR.
Values were normalised to levels
of β-actin (n=4). b Quantifica-
tion of expression of GLP1R by
iNKT cells measured by real-
time PCR; expression was also
measured on a GLP-1R-negative
HEK-293 cell line as a negative
control; n=3; †p<0.0001. c
Flow cytometry dot plots show-
ing representative HEK-293 cell
line, CD3+ T cell line and iNKT
cell line stained with the mAb
GLP-1R phycoerythrin (PE) and
mAbs for either CD3 APC
(Tcells) or iNKTcell TCR FITC
(iNKT cells). FMO, Flow Minus
One control for each cell line.
Gates were determined by FMO
and unstained samples (not
shown) (n=5)
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However, GLP-1 showed dose-dependent inhibitory effects
on the ability of αGalCer-loaded CD1d-transfected C1R
cells to induce IFN-γ and IL-4 production in iNKT cells
(Fig. 3c, d). As the GLP-1R antagonist exendin 9-39
abrogated the capacity of GLP-1 to modulate iNKT cell
cytokine production, the above inhibitory effects of GLP-1
on stimulated iNKT cells must be mediated via GLP-1R
(Fig. 4a, b). To determine whether GLP-1 modulation was
due to interference in the interaction between CD1d/
αGalCer and the T cell receptor complex, we stimulated
iNKT cells with PMA/ionomycin in the absence and
presence of GLP-1. We observed a significant reduction in
cytokine (IFN-γ and IL-4) upon the addition of GLP-1 to
stimulated iNKT cell cultures (Fig. 4c, d), indicating that
GLP-1 does not directly target the CD1d/TCR complex
interaction.
The GLP-1 analogue liraglutide modulates iNKT cell
cytokine production, but not cytolytic degranulation GLP-
1 has a very short half-life in vivo and thus longer-acting
analogues, such as liraglutide, are used in the clinical
setting. We investigated whether liraglutide could mimic the
regulatory effects of endogenous GLP-1 on iNKT cells. As
seen with native GLP-1, the GLP-1 analogue significantly
decreased production of IFN-γ and IL-4 (p<0.0001;
Fig. 5a). Finally, we investigated whether the GLP-1
analogue modulated the cytolytic degranulation of stimu-
lated iNKT cells, but observed no effect on mobilisation of
CD107+ cytolytic granules (Fig. 5c).
Discussion
We have observed an improvement in psoriasis following
GLP-1 therapy in our index patient and two other participants
with obesity and type 2 diabetes. We have demonstrated the
presence of iNKTcells in psoriasis lesions, associated with a
relative depletion in circulating iNKT cell number, and a
reversal of this ratio following 6 weeks of therapy with a
GLP-1 analogue in the two non-index participants. GLP-1R
was expressed on iNKT cells and modulated cytokine
production in vitro following stimulation with native GLP-1
or the GLP-1 analogue, liraglutide. The GLP-1 analogue did
not inhibit iNKTcell cytotoxicity function.
iNKT cells have been described as the ‘Swiss-Army
knife’ of the immune system [24]. They represent less than
1% of all peripheral blood T cells, but even so are potent
iNKT cells
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Fig. 3 GLP-1 modulates iNKTcell cytokines. IFN-γ (a) and IL-4 (b)
production by iNKT cells (1×105) after 24 h co-culture at a 1:1 ratio
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concentrations were measured by ELISA and analysed using Graph-
Pad Prism (n=3). *p<0.05, †p<0.005, ‡p<0.0001
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drivers of innate and acquired immune responses. Follow-
ing activation, iNKT cells are able to rapidly produce large
quantities of IFN-γ, IL-4 and granulocyte-macrophage
colony-stimulating factor, as well as multiple other cyto-
kines and chemokines (e.g. IL-2, IL-10 and TNF-α). In this
way, iNKT cells mediate both anti-inflammatory Th2-type,
regulatory T cell-type and pro-inflammatory Th1-type
immune responses [14].
Previous studies have demonstrated natural killer cells
and NKT cells in psoriasis plaques to be associated with
reduced numbers in the circulation [25, 26]. It is also
known that psoriatic keratinocytes are enriched in CD1d,
the molecule that presents glycolipid antigen to iNKT cells
[27], and that a CD1d reactive T cell line from a patient
with psoriasis induced psoriasis in a mouse model [28]. We
have demonstrated a reduction in psoriatic plaque iNKTcell
number and an increase in circulatory iNKT cell number,
following 6 weeks of GLP-1 analogue therapy. By contrast,
a previous study investigated the stability of iNKT cell
frequency over time and found that healthy donors
displayed constant levels over a period of 10 months [29].
GLP-1 has been shown to inhibit chemokine-induced
migration of human CD4-positive lymphocytes in vitro, a
critical step in vascular atherosclerotic plaque development
[22]. Inhibition of dipeptidyl peptidase-4 enzymatic degra-
dation of GLP-1 prevented recruitment of pro-inflammatory
macrophages into visceral fat in a mouse model of type 2
diabetes [30]. These modulatory effects of GLP-1 on
immune cell subsets may have important implications for
a range of inflammatory and autoimmune conditions.
The established role of GLP-1 is the regulation of
postprandial glucose excursions by stimulating insulin secre-
tion, inhibiting glucagon release and causing a delay in gastric
emptying. However, a growing body of literature has reported
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important extra-pancreatic effects of native GLP-1 and GLP-1
receptor agonists. Cardiovascular [31–33], neuroprotective
[34–36] and anti-inflammatory [37, 38] effects have been
described, along with potential therapeutic implications for
multiple disease states. GLP-1 therapy has been shown to
delay the onset of diabetes and restore normoglycaemia in
mouse models of type 1 diabetes [39, 40]. The beneficial
effects of GLP-1 in type 1 diabetes are attributed to trophic
and cytoprotective effects on pancreatic beta cells. In addition,
there is evidence for an immunoregulatory role, with reports
of a shift in cytokine production by islet-infiltrating leucocytes
[39] and of modulation of regulatory T cells [21, 41].
The GLP-1R has been demonstrated in murine immune
tissues [20], and on T and B lymphocytes from mice [20,
21] and humans [22]. We have now demonstrated that GLP-
1R is expressed on human iNKT cells. Unlike conventional
T cells, iNKT cells are innate immune cells, capable of
powerful anti-tumour cytotoxicity responses and rapid
cytokine production following direct antigen stimulation.
The balance of pro- and anti-inflammatory cytokines
produced influences the inflammatory environment and
the subsequent adaptive immune response.
The GLP-1R on iNKT cells is functional and signals in
response to GLP-1. This conclusion is based on the ability
of GLP-1 to promote increased levels of cAMP and induce
phosphorylation of the downstream transcription factor
CREB. These are typical responses of receptors like GLP-
1R, which signals via the Gs protein to activate adenylate
cyclase and increase levels of cAMP. Kim et al. reported
that treatment of mice with a dipeptidyl peptidase-IV (DPP-
IV) inhibitor resulted in an increase in cAMP levels, but the
same was not observed with GLP-1 treatment [23]. We have
now demonstrated that activation of GLP-1R on iNKTcells
results in a significant increase in cAMP levels. The
difference in findings may be explained by our use of a
DPP-IV-resistant GLP-1 analogue. Native GLP-1 is rapidly
degraded by DPP-IV in the circulation and has a half-life of
less than 1 to 2 min [42], whereas liraglutide, a GLP-1
analogue, has a half-life of 13 h [43]. It is also of interest
that GLP-1 promotes activation of the transcription factor
CREB. The latter is known to regulate expression of anti-
inflammatory genes such as IL10 [44], and it is intriguing to
speculate that some of the therapeutic effects of liraglutide
observed in the present study in psoriatic patients may be
related to CREB-induced production of anti-inflammatory
proteins. This is worthy of future investigation.
The addition of native GLP-1 or the GLP-1 analogue to
the iNKT cell co-cultures in vitro resulted in modulation of
biological activity, altering production of the cytokines IFN-
γ and IL-4. GLP-1 modified the cytokine production but
not the cytolytic activity of activated iNKT cells. We
suggest that GLP-1 is immunoregulatory as opposed to
immunosuppressive. The ability of GLP-1 to prime and
inhibit iNKT cell cytokine production supports previous
work indicating an immune cell regulatory role for this
hormone [20–23, 39]. The GLP-1R antagonist exendin 9-
39 was shown to block the modulation of iNKT cell
cytokine production by GLP-1. This confirms that the
modulation observed in iNKT cell cytokine production is
mediated by GLP-1R activation.
The patients in this report had subjective improvement of
psoriasis symptoms within 48 h of starting GLP-1 analogue
therapy, prior to significant weight loss. In addition, the first
patient (index patient) displayed improvement with initial GLP-
1 agonist therapy, deterioration upon withdrawal and rapid
improvement following re-treatment with a GLP-1 analogue. In
a murine model, Hadjiyanni et al. reported that lymphocytes
from Glp1−/− mice were hyperproliferative in response to
mitogenic stimulation, suggesting that GLP-1 may control
lymphocyte proliferation in mice [21]. Our data suggest that
the rapid clinical improvement observed in these psoriasis
patients may be secondary to direct regulation of iNKT cells
by a GLP-1 analogue. This is supported by alterations in
iNKTcell distribution in vivo and cytokine production in vitro.
Liraglutide therapy was commenced in the two non-
index study participants following the observed improve-
ment in psoriasis in the index patient. Glycaemic control
was excellent at baseline and remained unchanged. Both
non-index participants in the study lost weight after 6 weeks
of therapy. Weight loss has previously been shown to
positively affect circulating immune cell function in mice
[45] and humans [46]. In particular, bariatric surgery-
induced weight loss was shown to reverse impairments in
natural killer cell activity and natural killer cell-related
cytokine synthesis [47]. It is difficult to determine to what
exact extent reduced energy intake or changes in adipose
tissue mass may contribute to the noted changes in iNKT
cell function. However, all patients reported symptom relief
within days of commencing treatment. Expression of the
GLP-1R on the iNKT cell and modulation of cytokine
production in vitro suggest a specific GLP-1-mediated
effect, further supported by the inhibition of these effects
by the GLP-1R antagonist exendin (9-39).
Psoriasis has been shown to improve following Roux-
en-Y gastric bypass (RYGB) surgery [48]. This is thought
to be secondary to substantial weight loss and associated
improvements in metabolic and inflammatory markers.
RYGB also results in an early and sustained increase in
postprandial GLP-1 levels [49]. The in vitro effects of GLP-
1 analogues on iNKT cells demonstrated in the current
study suggest that the improvement in psoriasis following
RYGB may be mediated, at least in part, by the effect of
GLP-1 on iNKT cell cytokine production.
This study focused exclusively on human iNKTcells and
indicates that GLP-1 and GLP-1-based therapies directly
influence human immune function. While the effects seen
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in this report are positive in psoriasis, extensive research is
needed to investigate the potential beneficial or adverse
effects of direct GLP-1–immune cell interactions. The
observation that GLP-1 therapy restores circulating iNKT
cell number, directly primes a resting iNKTcell and inhibits
a stimulated iNKT cell further strengthens the link between
the endocrine and human immune system, indicating
potential new therapeutic applications for GLP-1 therapies.
Acknowledgements The authors would like to thank the UCD
Newman Fellowship program for funding A.E. Hogan.
Contribution statement A.E.H., A.M.T., T.A., M.A.C., G.G., V.
O’R. and R.J. contributed to the experimental design, data collection,
analysis and manuscript preparation. A.E.H., J.O’C., P.N.M., D.G.D.,
L.L., B.K. and D.O’S. contributed to the experimental design,
manuscript preparation, data analysis and intellectual input. All
authors have approved the final version of the paper.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,
Gelfand JM (2006) Prevalence of cardiovascular risk factors in
patients with psoriasis. J Am Acad Dermatol 55:829–835
2. Gisondi P, Tessari G, Conti A et al (2007) Prevalence of metabolic
syndrome in patients with psoriasis: a hospital-based case–control
study. Br J Dermatol 157:68–73
3. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M
(2006) Increased prevalence of the metabolic syndrome in
patients with moderate to severe psoriasis. Arch Dermatol Res
298:321–328
4. Qureshi AA, Choi HK, Setty AR, Curhan GC (2009) Psoriasis
and the risk of diabetes and hypertension: a prospective study of
US female nurses. Arch Dermatol 145:379–382
5. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and
diabetes. J Clin Invest 115:1111–1119
6. Spah F (2008) Inflammation in atherosclerosis and psoriasis:
common pathogenic mechanisms and the potential for an
integrated treatment approach. Br J Dermatol 159(Suppl 2):10–
17
7. Mallbris L, Akre O, Granath F et al (2004) Increased risk for
cardiovascular mortality in psoriasis inpatients but not in out-
patients. Eur J Epidemiol 19:225–230
8. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ,
Troxel AB (2006) Risk of myocardial infarction in patients with
psoriasis. JAMA 296:1735–1741
9. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB
(2002) Overweight and obesity as determinants of cardiovascular
risk: the Framingham experience. Arch Intern Med 162:1867–
1872
10. Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C,
O'Shea DB (2009) Are natural killer cells protecting the metaboli-
cally healthy obese patient? Obesity (Silver Spring) 17:601–605
11. Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG,
O'Farrelly C (2009) Invariant NKT cells and CD1d(+) cells amass
in human omentum and are depleted in patients with cancer and
obesity. Eur J Immunol 39:1893–1901
12. Liu TY, Uemura Y, Suzuki M et al (2008) Distinct subsets of
human invariant NKT cells differentially regulate T helper
responses via dendritic cells. Eur J Immunol 38:1012–1023
13. Peternel S, Kastelan M (2009) Immunopathogenesis of psoriasis:
focus on natural killer T cells. J Eur Acad Dermatol Venereol
23:1123–1127
14. Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H
(2010) The specialized iNKT cell system recognizes glycolipid
antigens and bridges the innate and acquired immune systems
with potential applications for cancer therapy. Int Immunol 22:1–6
15. Molling JW, Langius JA, Langendijk JA et al (2007) Low levels
of circulating invariant natural killer T cells predict poor clinical
outcome in patients with head and neck squamous cell carcinoma.
J Clin Oncol 25:862–868
16. Tudhope SJ, von Delwig A, Falconer J et al (2010) Profound
invariant natural killer T-cell deficiency in inflammatory arthritis.
Ann Rheum Dis 69:1873–1879
17. Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S (2007)
Activation of invariant natural killer Tcells by synthetic glycolipid
ligands suppresses autoantibody-induced arthritis. Arthritis
Rheum 56:1836–1845
18. Girard J (2008) The incretins: from the concept to their use in the
treatment of type 2 diabetes. Part A: Incretins: concept and
physiological functions. Diabetes Metab 34:550–559
19. Holst JJ (2007) The physiology of glucagon-like peptide 1.
Physiol Rev 87:1409–1439
20. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ (2008) Exendin-
4 modulates diabetes onset in nonobese diabetic mice. Endocri-
nology 149:1338–1349
21. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ (2010)
Glucagon-like peptide-1 receptor signalling selectively regulates
murine lymphocyte proliferation and maintenance of peripheral
regulatory T cells. Diabetologia 53:730–740
22. Marx N, Burgmaier M, Heinz P et al (2010) Glucagon-like
peptide-1(1-37) inhibits chemokine-induced migration of human
CD4-positive lymphocytes. Cell Mol Life Sci 67:3549–3555
23. Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl
peptidase IV inhibition with MK0431 improves islet graft survival
in diabetic NOD mice partially via T-cell modulation. Diabetes
58:641–651
24. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L (2008) CD1d-
restricted iNKT cells, the ‘Swiss-Army knife’ of the immune
system. Curr Opin Immunol 20:358–368
25. Cameron AL, Kirby B, Fei W, Griffiths CE (2002) Natural killer and
natural killer-Tcells in psoriasis. Arch Dermatol Res 294:363–369
26. Cameron AL, Kirby B, Griffiths CE (2003) Circulating natural
killer cells in psoriasis. Br J Dermatol 149:160–164
27. Bonish B, Jullien D, Dutronc Y et al (2000) Overexpression of
CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-
gamma production by NK-T cells. J Immunol 165:4076–4085
28. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA (2000)
Characterization of a T cell line bearing natural killer receptors
and capable of creating psoriasis in a SCID mouse model system.
J Dermatol Sci 24:212–225
29. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A
(2002) Testing the NKT cell hypothesis of human IDDM
pathogenesis. J Clin Invest 110:793–800
30. Shirakawa J, Fujii H, Ohnuma K et al (2011) Diet-induced
adipose tissue inflammation and liver steatosis are prevented by
DPP-4 inhibition in diabetic mice. Diabetes 60:1246–1257
31. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M (2011)
Cardiovascular comorbidities of type 2 diabetes mellitus: defining
Diabetologia
the potential of glucagonlike peptide-1-based therapies. Am J Med
124:S35–S53
32. Nikolaidis LA, Mankad S, Sokos GG et al (2004) Effects of
glucagon-like peptide-1 in patients with acute myocardial infarc-
tion and left ventricular dysfunction after successful reperfusion.
Circulation 109:962–965
33. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ,
Husain M (2008) Cardioprotective and vasodilatory actions of
glucagon-like peptide 1 receptor are mediated through both
glucagon-like peptide 1 receptor-dependent and -independent
pathways. Circulation 117:2340–2350
34. Holst JJ, Burcelin R, Nathanson E (2011) Neuroprotective
properties of GLP-1: theoretical and practical applications. Curr
Med Res Opin 27:547–558
35. Lerche S, Brock B, Rungby J et al (2008) Glucagon-like peptide-1
inhibits blood–brain glucose transfer in humans. Diabetes 57:325–331
36. Mcclean PL, Gault VA, Harriott P, Hölscher C (2009) Glucagon-
like peptide-1 analogues enhance synaptic plasticity in the brain: a
link between diabetes and Alzheimer’s disease. Eur J Pharmacol
630:158–162
37. Kodera R, Shikata K, Kataoka HU et al (2011) Glucagon-like
peptide-1 receptor agonist ameliorates renal injury through its
anti-inflammatory action without lowering blood glucose level in
a rat model of type 1 diabetes. Diabetologia 54:965–978
38. Hattori Y, Jojima T, Tomizawa A et al (2010) A glucagon-like
peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide
production and exerts anti-inflammatory action in endothelial
cells. Diabetologia 53:2256–2263
39. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M,
Rabinovitch A (2008) Combination therapy with glucagon-like
peptide-1 and gastrin restores normoglycemia in diabetic NOD
mice. Diabetes 57:3281–3288
40. Zhang J, Tokui Y, Yamagata K et al (2007) Continuous stimulation
of human glucagon-like peptide-1 (7-36) amide in a mouse model
(NOD) delays onset of autoimmune type 1 diabetes. Diabetologia
50:1900–1909
41. Xue S, Wasserfall CH, Parker M et al (2008) Exendin-4 therapy in
NOD mice with new-onset diabetes increases regulatory T cell
frequency. Ann N YAcad Sci 1150:152–156
42. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B,
Holst JJ (1995) Both subcutaneously and intravenously
administered glucagon-like peptide I are rapidly degraded from
the NH2-terminus in type II diabetic patients and in healthy
subjects. Diabetes 44:1126–1131
43. Deacon CF (2004) Therapeutic strategies based on glucagon-like
peptide 1. Diabetes 53:2181–2189
44. Mellett M, Atzei P, Jackson R, O’Neill LA, Moynagh PN (2011)
Mal mediates TLR-induced activation of CREB and expression of
IL-10. J Immunol 186:4925–4935
45. Lamas O, Martinez JA, Marti A (2004) Energy restriction restores
the impaired immune response in overweight (cafeteria) rats.
J Nutr Biochem 15:418–425
46. Tanaka S, Inoue S, Isoda F et al (1993) Impaired immunity in
obesity: suppressed but reversible lymphocyte responsiveness. Int
J Obes Relat Metab Disord 17:631–636
47. Moulin CM, Marguti I, Peron JPS, Halpern A, Rizzo LV (2011)
Bariatric surgery reverses natural killer (NK) cell activity and NK-
related cytokine synthesis impairment induced by morbid obesity.
Obes Surg 21:112–118
48. Hossler EW, Maroon MS, Mowad CM (2011) Gastric bypass
surgery improves psoriasis. J Am Acad Dermatol 65:198–200
49. Mingrone G (2008) Role of the incretin system in the remission of
type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc
Dis 18:574–579
Diabetologia
